Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
TheFly reported on June 15 that UBS initiated coverage of JBIO with a Buy rating and a $45 price target.
Jade Biosciences Inc. (JBIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,671,083 | $81,571,464 | 0.71% | |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 2,857,405 | $63,491,539 | 1.19% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 1,910,812 | $42,458,243 | 0.06% | |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,846,982 | $41,039,940 | 0.1% | |
| 5. | Avidity Partners Management David Witzke And Michael Gregory | 1,700,708 | $37,789,732 | +22% | 6.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.40 | 6,000 | $44,400.00 | 6,000 | 2025-05-16 | Filing | |
| $1.67 | 928,110 | $1,549,943.70 | 7,893,678 | 2024-06-17 | Filing | |
| $14.00 | 500,000 | $7,000,000.00 | 2,030,691 | 2021-07-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.03 | 15,000 | $375,450.00 | 5,022 | 2024-06-14 | Filing | |
| $25.00 | 10,600 | $265,000.00 | 0 | 2024-06-14 | Filing | |
| $24.50 | 6,000 | $147,000.00 | 5,602 | 2024-06-13 | Filing | |
| $21.86 | 86 | $1,879.96 | 5,602 | 2024-05-17 | Filing | |
| $21.07 | 3,914 | $82,451.54 | 5,688 | 2024-05-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,126,877 | $202,799,207 | 0.01% | |
| 2. | 6,273,262 | $139,369,006 | 0.06% | |
| 3. | 4,553,494 | $101,178,637 | 6.69% | |
| 4. | 3,220,364 | $71,556,488 | 2.17% | |
| 5. | 3,057,996 | $67,948,671 | 1.43% |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target.
9 Overlooked Growth Stocks to Buy
On January 12, Victoria Greene, Founding Partner and CIO at G Squared Private Wealth, joined CNBC to discuss her current market outlook, selecting 'Fundamentals' as her word of the day.
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target.
11 Best Micro-Cap Stocks to Invest in According to Analysts
Micro-cap companies, generally referring to publicly traded businesses with less than $300 million in market capitalization, are among the most volatile and high-risk investments in the stock market.
Hedge Fund Resource Center